

Dr. Hessam Kakavand, PharmD

Contact Information

Email: hessamkakavand@yahoo.com

Tel: 44604800

extention:

Address: Kazem Besarati St., Kabiri Tameh Ave., Shahid Hemmat Expy, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.

Academic Rank Group

Assistant Professor of Clinical Pharmacy

EDUCATION

Year

PhD in Clinical Pharmacy (Tehran University of Medical Sciences)

2020

PharmD (Islamic Azad University of Tehran Medical Sciences)

2016

SKILLS

Board Certified Pharmacotherapy Specialist

Certification in Conducting Randomized Controlled Trials; Investigator in Several International RCTs (e.g., INSPIRATION, INSPIRATION-S, and COATED-AIR)

Systematic Reviews and Meta-Analysis (Certified)

Reviewer at Several International Journals (e.g., Thrombosis Research, Journal of Clinical Lipidology, International Journal of Cardiology, American Heart Journal, BMC Cardiovascular Disorders, Lipids in Health and Disease, Cardiovascular Diabetology, Heliyon, Clinical Therapeutics, Contemporary Clinical Trials, etc.)

Language: Persian, English (IELTS Academic Band Score: 7.5)

PRESENTATIONS

1. Lipid-Lowering Therapies in Patients with ASCVD; International Congress on Cardiovascular Updates; September 2025
2. Pharmacotherapy Tips for Acute Heart Failure Management; International Congress on Cardiovascular Updates; September 2025
3. Antiarrhythmic Agents in Premature Beats; International Congress on Cardiovascular Updates; September 2025
4. Pharmacotherapy of Chronic Venous Insufficiency; The 14th Conference of Iranian Clinical Pharmacy; June 2025
5. Arrhythmia and Conduction Abnormalities Associated with Anticancer Medications; 10th Iranian Joint Cardiovascular Congress; May 2025
6. Walking a Tightrope: Antithrombotic Therapy in Challenging Scenarios; 10th Iranian Joint Cardiovascular Congress; May 2025
7. Antiplatelet Therapy in Patients with non-ST-Elevation Acute Coronary Syndromes; Tehran Heart Center Annual Congress; February 2025
8. Updates on Antithrombotic Agents; The Third Educational Festival of the Medical Council of Iran; December 2024
9. What's New in Cardiovascular Pharmacotherapy? The Third Educational Festival of the Medical Council of Iran; December 2024
10. Peri-operative Medication Management in Patients Undergoing Orthopedic Surgeries; 32nd Annual Congress of Orthopedic Surgeons Association

11. Gastroprotection in Patients with Coronary Artery Disease; International Congress on Cardiovascular Updates; September 2024
12. Advanced Antithrombotic Stewardship Session for Clinical Pharmacists; The 13th Conference of Iranian Clinical Pharmacy; June 2024
13. VTE: Case-Based Discussion on Cancer-Associated Venous Thromboembolism; 9th Iranian Joint Cardiovascular Congress
14. Updates on Pharmacotherapy of Essential Hypertension; Updates on the Pharmacotherapy of Chronic Diseases Congress; February 2024
15. Updates on Anticoagulation with Warfarin, the Safest Method for INR Monitoring; Rajaie Cardiovascular Medical and Research Institute; December 2023
16. Primary Prevention of Atherosclerotic Cardiovascular Disease; The Second Educational Festival of the Medical Council of Iran; December 2023
17. What's New on Antithrombotic Medications; The Second Educational Festival of the Medical Council of Iran; December 2023
18. Venous Thromboembolism Challenges; International Congress on Cardiovascular Updates; September 2023
19. Pharmacotherapy of Type II Diabetes Mellitus; Iranian Clinical Pharmacy Association CME; July 2023
20. Pharmacotherapy of Type I Diabetes Mellitus; Iranian Clinical Pharmacy Association CME; July 2022
21. Pharmacotherapy of Type I Diabetes Mellitus; Iranian Clinical Pharmacy Association CME; November 2021
22. Pharmacotherapy of Heart Failure; Iran University CME; September 2021
23. Pharmacotherapy of Dyslipidemia; Iranian Clinical Pharmacy Association CME; April 2021
24. Pharmacotherapy of Multiple Sclerosis; Iranian Clinical Pharmacy Association CME; September 2020
25. Evaluating the Role of IV Pentoxifylline on Myocardial Reperfusion Injury in Patients Following P-PCI; ACC/AHA 2020 Congress (Webinar); April 2020
26. Practical Points for Novel Antithrombotic Agents, Nursing Panel; Tehran Heart Center; January 2020
27. Practical Points for Apixaban at Tehran Thrombosis Congress; Tehran Heart Center; November 2019
28. Pharmacotherapy of Rheumatoid Arthritis; Iranian Clinical Pharmacy Association CME; November 2019
29. Prevention of Opportunistic Infections in Patients Receiving Biologic Agents or Targeted Immunomodulators; Infectious Disease Grand Round; Imam Khomeini Hospital; August 2018
30. A Randomized Clinical Trial Comparing Tea Tree Oil vs. Chlorhexidin for Decolonization of MRSA in Pediatric Patients; 18th Asian Conference on Clinical Pharmacy (ACCP 2018); June 2018
31. Stress Ulcer Prophylaxis in Medically Ill Patients; Neurology Grand Round; Sina Hospital; May 2018
32. Pharmacotherapy of Chronic Coronary Syndromes; Iranian Clinical Pharmacy Association CME; April 2018
33. Pharmacotherapy of Dyslipidemia; Islamic Azad University of Medical Sciences Workshop for Pharmacy Students; April 2018
34. Pharmacotherapy of Chronic Coronary Syndromes; Islamic Azad University of Medical Sciences Workshop for Pharmacy Students; April 2018
35. Pharmacotherapy of Type II Diabetes Mellitus; Iranian Clinical Pharmacy Association CME; November 2017
36. Pharmacotherapy of Dyslipidemia; Iranian Clinical Pharmacy Association CME; August 2017

37. Pharmacotherapy of Osteoarthritis; Iranian Clinical Pharmacy Association CME; September 2017
 38. Medical Applications Workshops (6 times); 2017-2018
-

PUBLICATIONS

Journal Papers:

1. The Impact of *CYP3A4/5* Polymorphism on Anti-Factor Xa Activity in Iranian Patients with Atrial Fibrillation Receiving Rivaroxaban. *Iranian Red Crescent Medical Journal*; September 2025
2. A Multifaceted Intervention to Mitigate the Adverse Cardiovascular Effects of Air Pollution: A Feasibility Randomized Controlled Trial. *Journal of Cardiovascular Pharmacology*; June 2025
3. Empagliflozin to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery: Rationale and Design of the EMPOAF Trial. *PACE - Pacing and Clinical Electrophysiology*; June 2024
4. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. *Nature Reviews Cardiology*; March 2024
5. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. *Thrombosis and Haemostasis*; May 2023
6. Evaluating the Role of Intravenous Pentoxifylline Administration on Primary Percutaneous Coronary Intervention Success Rate in Patients with ST Elevation Myocardial Infarction (PENTOS-PCI). *Naunyn-Schmiedeberg's Archives of Pharmacology*; March 2023
7. A Stepwise Approach to Prescribing Novel Lipid-Lowering Medications. *Journal of Clinical Lipidology*; October 2022
8. Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI); *Journal of Cardiovascular Pharmacology*; June 2022
9. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial; *bmj*; January 2022.
10. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review; *Journal of American College of Cardiology*; October 2021
11. Use of Investigational Agents with Antithrombotic Properties for COVID-19. *Journal of Thrombosis and Haemostasis*; September 2021.
12. Intermediate vs Standard-dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to ICU: Final Results from the INSPIRATION Trial. *Thrombosis and Haemostasis*; April 2021
13. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. JACC State-of-the-Art Review. *Journal of American College of Cardiology*; April 2021
14. Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention; *Journal of Cardiovascular Pharmacology*; April 2021
15. Effect of Intermediate-Dose vs. Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. *JAMA*; March 2021
16. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective; *Cardiovascular Drugs and Therapy*; July 2020
17. Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19); *Journal of Cardiovascular Pharmacology*; April 2020

RESEARCH INTRESTS

Cardiovascular Pharmacotherapy

Thrombosis and Hemostasis, Antithrombotic Therapy

Dyslipidemia, Lipid-Lowering Therapies

Ischemia/Reperfusion Injury, Cardioprotection

Cardio-Oncology, Cancer-Associated Thrombosis

Randomized Controlled Trials

LINKS

<https://orcid.org/0000-0001-6719-4856>

<https://www.scopus.com/authid/detail.uri?authorId=57216803165>

<https://scholar.google.com/citations?user=ME41cLMAAAAJ&hl=en>

https://isid.research.ac.ir/Hessam_Kakavand

<https://www.researchgate.net/profile/Hessam-Kakavand>